Bionime Stock

Bionime FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bionime (4737.TW) as of Aug 16, 2026 is -114.49 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 246.27 % — a change of -146.49% (lower).

FCF Conversion

-114.49 %

YoY

-146.49%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bionime is 2026 -114.49 % . FCF Conversion Rate (FCF/EBITDA) of Bionime was 2025 246.27 % . It decreases by -146.49% lower compared to the previous year.
Access this data via the Eulerpool API

Bionime Stock analysis

What does Bionime do? Bionime Corp is a company that was founded in 2003 and specializes in the development and manufacture of medical devices for measuring blood sugar levels and other cardiovascular tests. Bionime is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionime stock

FCF Conversion Rate (FCF/EBITDA) of Bionime is -114.49 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Bionime changed from 246.27 % to -114.49 %, representing a -146.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bionime since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bionime with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Bionime

All Key Metrics — Bionime